Halozyme CEO Helen Torley Sells $6 Million of Stock After Exercising Options
Halozyme Therapeutics President and Chief Executive Helen Torley sold $6 million of the company's stock over three trading days after exercising stock options, according to a Form 4 filed Monday.
Torley exercised options on 20,000 shares on each of Nov. 12, Nov. 13 and Nov. 16, for 60,000 shares in total, at exercise prices of $16.65 and $18.41 a share. She sold 60,000 shares across those same days.
The sales were made at weighted average prices ranging from $96.848 to $101.72 a share and totaled $6,000,685.54, based on the filing's reported prices.
A plan set in 2025
The exercises and sales were made under a written Rule 10b5-1 trading plan Torley adopted on Dec. 3, 2025, according to a footnote. The shares sold came from options with 10-year terms expiring in February 2028 and February 2029, the filing says.
The options were originally granted on Feb. 14, 2018, and Feb. 12, 2019, according to the Form 4.
What she still owns
Torley held 767,780 Halozyme shares directly after the last sale on Nov. 16, the same number she held before the first exercise.
By the numbers
- Options exercised: 60,000 shares at $16.65 and $18.41
- Shares sold: 60,000, Nov. 12 to Nov. 16, 2026
- Sale value: $6,000,685.54
- Weighted average prices: $96.848 to $101.72
- Shares held afterward: 767,780
Sources
- Form 4, Helen Torley, Halozyme Therapeutics, Inc., filed Nov. 16, 2026, accession 0001159036-26-000147
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.